Targets › RPOB
1 program from 1 company in 1 trial: 1 Phase 4; Infectious disease; next expected readout Mar 2027.
Open in Phaseline: the race on RPOB, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Leiden University Medical Center | Levofloxacin DNA gyrase inhibitor; Topoisomerase IV inhibitor | RPOB | Phase 4 | Prosthetic-joint Infection | Mar 2027 |
Prosthetic-joint Infection (1)
small molecule (1)
Leiden University Medical Center (1)
–
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.